High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of […]
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evolus Inc (EOLS) raises full-year guidance on strong portfolio growth and strategic expansion into skin quality with Profhilo partnership.
Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations. Globa
Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, companies that exhibit high growth potential and significant insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business.
Moby summary of Evolus, Inc.'s Q1 2026 earnings call
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year 2026 outlook for double-digit revenue growth and adjusted EBITDA profitability. First-quarter results
David Moatazedi: Thank you, Nareg, and good afternoon, everyone. Internationally, the business continues to deliver strong performance and is increasingly contributing to our growth trajectory as we expand our global footprint in key markets.
Evolus is back in focus after analysts revisited their price target framework, keeping the fair value unchanged at $14.67 per share. Some see the maintained target as confirmation that the core thesis is intact, while others read the previous $4 cut as a sign that expectations around long term revenue may have been reset. As you read on, you will see how to interpret this evolving analyst narrative and what to watch if you are tracking Evolus from here. Analyst Price Targets don't always...
The United States market has shown robust performance, rising 3.4% over the last week and an impressive 35% over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.
Evolus (NASDAQ:EOLS) executives told investors at Needham & Company’s 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) fill
The latest analyst work on Evolus keeps the modeled fair value steady at US$14.67 per share, even as several firms reduce their published price targets. Those cuts are tied less to a change in the core valuation inputs and more to how analysts interpret the softer preliminary 2025 net revenue outlook, the 2026 guide, and the scaled back long term narrative. As you read on, you will see how to approach this evolving setup and what to watch as the story continues to develop. Stay updated as the...
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]
Evolus (NASDAQ:EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers amid changing consumer sentiment. Speaking at the Leerink Conference, CEO Dav
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.